NASDAQ:ACOG Alpha Cognition Q3 2026 Earnings Date & Estimates $8.45 -0.20 (-2.31%) Closing price 04:00 PM EasternExtended Trading$8.37 -0.08 (-0.95%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alpha Cognition is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Alpha Cognition in Q3 2026Alpha Cognition is expected to post earnings of -$0.33 per share on revenue of $7.04 million. In the same quarter a year earlier Alpha Cognition reported -$0.30 per share on revenue of $2.84 million. Alpha Cognition last reported on August 13, 2026, posting -$0.40 per share and missing the -$0.3921 consensus estimate. Alpha Cognition has beaten the consensus EPS estimate in 3 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.33Expected Revenue$7.04 millionPrior-Year EPS-$0.30Prior-Year Revenue$2.84 millionExpected Revenue Growth+147.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.40 (Missed by -$0.0079)Last Quarter Revenue$6.00 millionEPS Beat Rate3 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Alpha Cognition Q3 2026 Earnings FAQ When does Alpha Cognition report Q3 2026 earnings? Alpha Cognition (NASDAQ:ACOG) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Alpha Cognition's Q3 2026 earnings call? Alpha Cognition's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Alpha Cognition? Analysts expect Alpha Cognition to post earnings of -$0.33 per share for Q3 2026. How much revenue is Alpha Cognition expected to report? The consensus revenue estimate for Alpha Cognition is $7.04 million for Q3 2026. Alpha Cognition Earnings HeadlinesAlpha Cognition Inc. (NASDAQ:ACOG) Stock Has Average Target Price of $18.00October 8, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG) and Travere Therapeutics (TVTX)October 3, 2026 | theglobeandmail.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | financialpost.comFAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | businesswire.comMajor Investor Quietly Ramps Up Stake in Alpha Cognition Inc.September 28, 2026 | tipranks.comSee More Alpha Cognition Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Cognition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Cognition and other key companies, straight to your email. Email Address About Alpha CognitionAlpha Cognition (NASDAQ:ACOG) (NASDAQ: ACOG) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative disorders, including Alzheimer’s disease and related cognitive conditions. The company’s work is centered on addressing unmet needs in the diagnosis, management and treatment of diseases that affect memory and cognitive function. Its lead commercial product is ZUNOVO (memantine hydrochloride extended-release capsules), a prescription therapy approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dementia of the Alzheimer’s type. The company is also advancing additional drug candidates, including ALPHA-1062, an investigational formulation of galantamine intended for potential use in Alzheimer’s disease. Alpha Cognition is headquartered in Vancouver, British Columbia, and serves the U.S. pharmaceutical market through its development and commercialization activities. The company is led by Chief Executive Officer Michael McFadden.View Alpha Cognition ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
